Anzeige
Mehr »
Mittwoch, 11.02.2026 - Börsentäglich über 12.000 News
Drohnen, Robotik, E-Autos: Diese Hightech-Aktie könnte jetzt zünden
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
110 Leser
Artikel bewerten:
(0)

Men Can Improve Erection Firmness and Duration with Vivaxa Cream, Now on Sale at Maxoderm.com

NEW YORK, Feb. 14, 2013 /PRNewswire/ --Male enhancement company Maxoderm, available online at http://www.Maxoderm.com, is now showcasing Vivaxa, one of its many available male creams. The Vivaxa formula is designed with special ingredients for users who wish to experience increased stamina in the bedroom.

(Logo: http://photos.prnewswire.com/prnh/20130214/PH60114LOGO )

"An abundance of male enhancement products are now available on the market, which may make singling out the effective ones quite difficult. However, learningabout the products' key ingredients is a good way to separate useful products from the rest. The result of any effective male enhancement product should be: enhanced libido, stamina, mood and size. L-arginine is thought to improve the action of nitric oxide and relax the muscles that surround blood vessels supporting the penis. This ingredient is essential to penile performance, and is found in Vivaxa," said Rica Lewis, Livestrong.com health and wellness contributor.

The patent-pending formula for Vivaxa includes a unique peptide sequence to create first-use results unlike those provided by similar male delay creams. Vivaxa is odorless and includes arginine, an amino acid shown to diminish hyper-excitability of the skin, which helps to extend the duration of intimate encounters.

Like all of Maxoderm's penis creams, Vivaxa is designed to take effect quickly. A five-to-10 minute application prior to sexual intercourse will delay the user's climax and provide additional stamina from beginning to end. As a topical solution, Vivaxa is also safer for many customers than traditional male enhancement pills. With no known side effects, the formula is well-suited for men concerned with their overall health as well as their sexual health.

The company's website outlines a schedule with the recommended frequency for Vivaxa applications during a user's first 12 weeks. For maximum results, Maxoderm suggests that men who use Vivaxa should apply the product four times during the first week, then five times in the second and third weeks. Six applications are advised for the fourth through the sixth weeks, with a gradual reduction down to only three applications during subsequent weeks.

Vivaxa is one of three formulas available from Maxoderm, which emphasizes different aspects of sexual health and ability. Maxoderm is designed to increase male sensation and allow its users to more easily achieve harder erections. Another solution, Connection Cream, is formulated to enhance the sexual experience for both male and female partners, creating more intense sensations for women and providing men with the improved erection quality and virility characteristic of Maxoderm products.

For a limited time, a special deal allows customers to save in the company's online store. Shoppers who purchase any of Maxoderm's three creams, including the featured formula Vivaxa, can receive a free month's supply for each two they order. The store carries these three-month bundles for only $79, a savings of $40 from the items' original prices. Additional discounts are available for customers who purchase two or more formulas in combination.

For more information about how to achieve longer-lasting, harder erections with Maxoderm products, visit the manufacturer's website at http://www.Maxoderm.com or call 1-800-461-4571. The company is also available on Facebook and Twitter at http://www.facebook.com/pages/Maxodermcom/325701534205269 and http://twitter.com/MaxodermOnline, respectively. The penis cream supplier also blogs about male enhancement at http://www.Maxoderm.com/blog.

Contact:

Yehuda Apfelbaum
718 569 1020

This press release was issued through eReleases® Press Release Distribution. For more information, visit http://www.ereleases.com.

SOURCE Maxoderm

© 2013 PR Newswire
Favoritenwechsel
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.